Download PDF
Thromb Haemost 2010; 104(01): 151-156
DOI: 10.1160/TH09-09-0663
Cardiovascular Biology and Cell Signalling
Schattauer GmbH

Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms

Giuseppe Cella
1   Cardiac, Thoracic and Vascular Sciences Dept, University of Padua, Padua, Italy
,
Marina Marchetti
2   Division of Immunohematology and Transfusion Medicine & Hemostasis and Thrombosis Center, Ospedali Riuniti, Bergamo, Italy
,
Fabrizio Vianello
1   Cardiac, Thoracic and Vascular Sciences Dept, University of Padua, Padua, Italy
,
Marina Panova-Noeva
2   Division of Immunohematology and Transfusion Medicine & Hemostasis and Thrombosis Center, Ospedali Riuniti, Bergamo, Italy
3   Department of Biochemistry, Laboratory for Clinical Thrombosis and Haemostasis, Maastricht University, Netherlands
,
Alfonso Vignoli
2   Division of Immunohematology and Transfusion Medicine & Hemostasis and Thrombosis Center, Ospedali Riuniti, Bergamo, Italy
,
Laura Russo
2   Division of Immunohematology and Transfusion Medicine & Hemostasis and Thrombosis Center, Ospedali Riuniti, Bergamo, Italy
,
Tiziano Barbui
4   Research Foundation, Ospedali Riuniti, Bergamo, Italy
,
Anna Falanga
2   Division of Immunohematology and Transfusion Medicine & Hemostasis and Thrombosis Center, Ospedali Riuniti, Bergamo, Italy
› Author Affiliations Financial support: This study was supported in part by grants from the “Associazione Italiana per la Ricerca sul Cancro (AIRC)”, and from the NIH Myeloproliferative Disorders Research Consortium, to A.F.
Further Information

Publication History

Received: 24 September 2009

Accepted after major revision: 26 February 2010

Publication Date:
23 November 2017 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Essential thrombocythaemia (ET) and polycythaemia vera (PV) are characterised by a high incidence of thrombotic complications due to highshear stress of the vessel wall, blood hyperviscosity and hypoxaemia, all factors responsible for chronic endothelial dysfunction and platelet and leukocyte activation. We evaluated the activation status of vascular cells in 18 consecutive ET and 14 PV patients by measuring the plasma levels of the nitric oxide derivatives (NOX) (i.e. nitrites and nitrates) and of soluble selectins of platelet (P-selectin), endothelial cell (P-selectin and E-selectin) and leukocyte (L-selectin) origin. The effect of hydroxyurea (HU) therapy on these parameters was also investigated. NOX were significantly (p<0.01) increased in ET patients treated with HU (11.5 ± 2.6 nM) compared to non-HU treated ET (1.41 ± 0.3 nM) and to controls (4.78 ± 2.49 nM). Multivariate analysis confirmed HU therapy as an independent predictor of higher NOX levels in ET. In addition, NOX significantly correlated with haematocrit. Plasma P-selectin was significantly elevated in ET (350 ± 40 ng/106 platelets) and PV (482 ± 53 ng/106 platelets) patients compared to controls (120 ± 8 ng/106 platelets). In PV, also E-selectin (23.8 ± 4.2 ng/ml) was significantly increased compared to controls (11.2 ± 1.1 ng/ml; p<0.01). P-selectin was significantly correlated to platelet (R=0.33; p=0.01) and leukocyte count (R=0.6; p=0.000), while E-selectin (R=0.34; p=.014) and sL-selectin (R=0.3; p=0.03) were correlated with leukocyte count only. In the multivariate analysis, NOX predicted increased levels of E-selectin in ET, but not in PV patients. Our data demonstrate that ET and PV are characterised by an altered pattern of soluble selectins and NOX. HU-mediated increase of NOMX levels could represent an additional antithrombotic mechanism of this drug.

Keywords

Nitric oxide - selectins - essential thrombocythemia - polycythemia vera - Hydroxyurea
 

  • References

  • 1 Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Critical Rev Oncol Hematol 1995; 20: 203-222.
    CrossrefPubMedGoogle Scholar
  • 2 Falanga A, Marchetti M, Vignoli A. et al Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523-530.
    CrossrefPubMedGoogle Scholar
  • 3 Falanga A, Marchetti M, Vignoli A. et al V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007; 35: 702-711.
    CrossrefPubMedGoogle Scholar
  • 4 Falanga A, Marchetti M, Barbui T. et al Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Sem Hematol 2005; 42: 239-247.
    CrossrefPubMedGoogle Scholar
  • 5 Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275-290.
    CrossrefPubMedGoogle Scholar
  • 6 Cines DB, Pollak ES, Buck CA. et al Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
    PubMedGoogle Scholar
  • 7 Falanga A, Marchetti M, Evangelista V. et al Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and poly-cythemia vera. Blood 2000; 96: 4261-4266.
    PubMedGoogle Scholar
  • 8 Freedman JE, Loscalzo J. Nitric oxide and its relationship to thrombotic disorders. J Thromb Haemost 2003; Jun 01 (06) 1183-8.
    CrossrefPubMedGoogle Scholar
  • 9 Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-2101.
    PubMedGoogle Scholar
  • 10 Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-512.
    CrossrefPubMedGoogle Scholar
  • 11 Cella G, Bellotto F, Tona F. et al Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001; 120: 1226-1230.
    CrossrefPubMedGoogle Scholar
  • 12 Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am J Hypertens 2001; 14: 44S-54S.
    CrossrefPubMedGoogle Scholar
  • 13 Blann AD, Tse W, Maxwell SJ. et al Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens 1994; 12: 925-928.
    PubMedGoogle Scholar
  • 14 Gearing AJ, Hemingway I, Pigott R. et al Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann NY Acad Sci 1992; 667: 324-331.
    CrossrefPubMedGoogle Scholar
  • 15 Jilma B, Fasching P, Ruthner C. et al Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb Haemost 1996; 76: 328-332.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Blann AD, Faragher EB, McCollum CN. Increased soluble P-selectin following myocardial infarction: a new marker for the progression of atherosclerosis. Blood Coagul Fibrinolysis 1997; 08: 383-390.
    CrossrefPubMedGoogle Scholar
  • 17 Michiels JJ, De Raeve H, Berneman Z. et al The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost 2006; 32: 307-340.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Keynes RG, Garthwaite J. Nitric oxide and its role in ischaemic brain injury. Curr Mol Med 2004; 04: 179-191.
    CrossrefPubMedGoogle Scholar
  • 19 Glover RE, Ivy ED, Orringer EP. et al Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol 1999; 55: 1006-1010.
    CrossrefPubMedGoogle Scholar
  • 20 Cortelazzo S, Finazzi G, Ruggeri M. et al Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New Engl J Med 1995; 332: 1132-1136.
    CrossrefPubMedGoogle Scholar
  • 21 Rejto L, Huszka M, Kaplar M. et al Effects of in vitro platelet activation on platelet derived nitric oxide production in healthy humans and in chronic myeloproliferative diseases with elevated platelet counts. Platelets 2003; 14: 283-286.
    CrossrefPubMedGoogle Scholar
  • 22 Ferlito S, Gallina M. Nitrite, endothelin and E-selectin plasma levels after arginine infusion in normal and vasculopathic subjects. Minerva Cardioangiologica 1998; 46: 471-477.
    PubMedGoogle Scholar
  • 23 Kayali Z, Herring J, Baron P. et al Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction. J Gastroenterol Hepatol 2009; 24: 1030-1037.
    CrossrefPubMedGoogle Scholar
  • 24 Caimi G, Montana M, Calandrino V. et al Nitric oxide metabolites (nitrite and nitrate) in young patients with recent acute myocardial infarction. Clin Hemorheol Microcirculation 2008; 40: 157-163.
    PubMedGoogle Scholar
  • 25 Shibata J, Hasegawa J, Siemens HJ. et al Hemostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis. Blood 2003; 101: 4416-4422.
    CrossrefPubMedGoogle Scholar
  • 26 Andre P. P-selectin in haemostasis. Br J Haematol 2004; 126: 298-306.
    CrossrefPubMedGoogle Scholar
  • 27 Karakantza M, Giannakoulas NC, Zikos P. et al Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera. Int J Hematol 2004; 79: 253-259.
    CrossrefPubMedGoogle Scholar
  • 28 Musolino C, Alonci A, Bellomo G. et al Myeloproliferative Disease: Markers of Endothelial and Platelet Status in Patients with Essential Thrombocythemia and Polycythemia Vera. Hematology (Amsterdam, Netherlands) 2000; 04: 397-402.
    PubMedGoogle Scholar
  • 29 Jilma B, Eichler HG, Becherer A. et al Kinetics of circulating selectin levels during bone marrow aplasia. Eur J Haematol 1998; 61: 36-41.
    PubMedGoogle Scholar
  • 30 Bang SM, Lee JS, Ahn JY. et al Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation. Thromb Haemost 2009; 101: 547-551.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Carobbio A, Finazzi G, Guerini V. et al Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109: 2310-2313.
    CrossrefPubMedGoogle Scholar